Neurodevelopmental, behavioral, and emotional symptoms in Becker muscular dystrophy.
Adolescent
Affective Symptoms
/ etiology
Anxiety
/ etiology
Attention Deficit Disorder with Hyperactivity
/ etiology
Child
Child, Preschool
Developmental Disabilities
/ etiology
Dystrophin
/ genetics
Female
Humans
Infant
Language Development Disorders
/ etiology
Learning Disabilities
/ etiology
Male
Muscular Dystrophy, Duchenne
/ complications
Mutation
Prevalence
Retrospective Studies
Young Adult
Becker muscular dystrophy
behavioral
cognitive impairment
dystrophin
emotional
fluoxetine
genetics
learning disabilities
neurodevelopmental
pharmacotherapy
Journal
Muscle & nerve
ISSN: 1097-4598
Titre abrégé: Muscle Nerve
Pays: United States
ID NLM: 7803146
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
19
03
2019
revised:
11
10
2019
accepted:
19
10
2019
pubmed:
28
10
2019
medline:
14
4
2020
entrez:
26
10
2019
Statut:
ppublish
Résumé
Becker muscular dystrophy (BMD) results in decreased dystrophin with implications for mental health. This is a retrospective case series of neurodevelopmental, behavioral, and emotional symptoms and respective pharmacotherapies of 70 patients with BMD. Fifty-four (77.1%) patients exhibited at least one symptom, and 19 (27.1%) patients exhibited four or more symptoms. The most prevalent symptoms were specific learning disabilities or special education needs (31.4%), inattention/hyperactivity (35.7%), language/speech delays (35.7%), and emotional or behavioral dysregulation (38.6%). Fisher's exact tests indicated that anxiety was more prevalent with mutations upstream of exon 30 (P = .049), but the prevalence of other symptoms did not differ with respect to mutation sites. Similarly, the number of symptoms individual patients with BMD exhibited did not differ with respect to mutation sites. Seventeen (24.3%) patients required pharmacotherapy to manage symptoms. Neurodevelopmental, behavioral, and emotional symptoms are prevalent in patients with BMD regardless of dystrophin gene mutation site.
Substances chimiques
Dystrophin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
156-162Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Worton RG, Thompson MW. Genetics of Duchenne muscular dystrophy. Annu Rev Genet. 1988;22:601-629.
Bushby KMD, Gardner-Medwin D. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. J Neurol. 1993;240(2):98-104.
Koenig M, Beggs AH, Moyer M, et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet. 1989;45(4):498-506.
Flanigan KM, Dunn DM, von Niederhausern A, et al. Nonsense mutation-associated Becker muscular dystrophy: interplay between exon definition and splicing regulatory elements within the DMD gene. Hum Mutat. 2011;32(3):299-308. https://doi.org/10.1002/humu.21426.
Hoffman EP, Kunkel LM, Angelini C, Clarke A, Johnson M, Harris JB. Improved diagnosis of Becker muscular dystrophy by dystrophin testing. Neurology. 1989;39(8):1011-1017.
Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol. 2003;2(12):731-740.
Mehler MF. Brain dystrophin, neurogenetics and mental retardation. Brain Res Brain Res Rev. 2000;32(1):277-307.
Sekiguchi M. The role of dystrophin in the central nervous system: a mini review. Acta Myol. 2005;24(2):93-97.
Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord. 2006;16(4):249-255. https://doi.org/10.1016/j.nmd.2006.01.010.
McDonald CM, Henricson EK, Abresch RT, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet. 2018;391(10119):451-461. https://doi.org/10.1016/S0140-6736(17)32160-8.
Markham LW, Kinnett K, Wong BL, Woodrow Benson D, Cripe LH. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscul Disord. 2008;18(5):365-370. https://doi.org/10.1016/j.nmd.2008.03.002.
Sawnani H, Horn PS, Wong B, et al. Comparison of pulmonary function decline in steroid-treated and steroid-naïve patients with Duchenne muscular dystrophy. J Pediatr. 2019;210:194-200.e2. doi: https://doi.org/10.1016/j.jpeds.2019.02.037
Archer JE, Gardner AC, Roper HP, Chikermane AA, Tatman AJ. Duchenne muscular dystrophy: the management of scoliosis. J Spine Surg. 2016;2(3):185-194. doi: https://doi.org/10.21037/jss.2016.08.05
Alman BA, Raza SN, Biggar WD. Steroid treatment and the development of scoliosis in males with Duchenne muscular dystrophy. J Bone Joint Surg Am. 2004;86(3):519-524. https://doi.org/10.2106/00004623-200403000-00009.
Conway KC, Mathews KD, Paramsothy P, et al. Neurobehavioral concerns among males with dystrophinopathy using population-based surveillance data from the Muscular Dystrophy Surveillance, Tracking, and Research Network. J Dev Behav Pediatr. 2015;36(6):455-463. https://doi.org/10.1097/DBP.0000000000000177.
Hinton VJ, Cyrulnik SE, Fee RJ, et al. Association of autistic spectrum disorders with dystrophinopathies. Pediatr Neurol. 2009;41(5):339-346. https://doi.org/10.1016/j.pediatrneurol.2009.05.011.
Young HK, Barton BA, Waisbren S, et al. Cognitive and psychological profile of males with Becker muscular dystrophy. J Child Neurol. 2008;23(2):155-162. https://doi.org/10.1177/0883073807307975.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
Bertrand J, Mars A, Boyle C, Bove F, Yeargin-Allsopp M, Decoufle P. Prevalence of autism in a United States population: the Brick Township, New Jersey, investigation. Pediatrics. 2001;108(5):1155-1161.
Newschaffer CJ, Croen LA, Daniels J, et al. The epidemiology of autism spectrum disorders. Annu Rev Public Health. 2007;28:235-258.
Ritvo ER, Freeman BJ, Pingree C, et al. The UCLA-University of Utah epidemiologic survey of autism: prevalence. Am J Psychiatry. 1989;146(2):194-199.
Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics. 2012;9(3):490-499. https://doi.org/10.1007/s13311-012-0135-8.
Altarac M, Saroha E. Lifetime prevalence of learning disability among US children. Pediatrics. 2007;119(Suppl 1):S77-S83.
Law J, Boyle J, Harris F, Harkness A, Nye C. Prevalence and natural history of primary speech and language delay: findings from a systematic review of the literature. Int J Lang Commun Disord. 2000;35(2):165-188.
Shevell M, Ashwal S, Donley D, et al. Practice parameter: evaluation of the child with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2003;60(3):367-380.
Thangarajh M, Spurney CF, Gordish-Dressman H, et al. Neurodevelopmental needs in young boys with Duchenne muscular dystrophy (DMD): observations from the Cooperative International Neuromuscular Research Group (CINRG) DMD Natural History Study (DNHS). PLoS Curr. 2018. https://doi.org/10.1371/currents.md.4cdeb6970e54034db2bc3dfa54b4d987.
Knight T, Steeves T, Day L, Lowerison M, Jette N, Pringsheim T. Prevalence of tic disorders: a systematic review and meta-analysis. Pediatr Neurol. 2012;47(2):77-90. https://doi.org/10.1016/j.pediatrneurol.2012.05.002.
Scahill L, Specht M, Page C. The prevalence of tic disorders and clinical characteristics in children. J Obsessive Compuls Relat Disord. 2014;3(4):394-400.
Melo M, Lauriano V, Gentil V, et al. Becker and limb-girdle muscular dystrophies: a psychiatric and intellectual level comparative study. Am J Med Genet. 1995;60(1):33-38.
Fullana MA, Mataix-Cols D, Caspi A, et al. Obsessions and compulsions in the community: prevalence, interference, help-seeking, developmental stability, and co-occurring psychiatric conditions. Am J Psychiatry. 2009;166(3):329-336. https://doi.org/10.1176/appi.ajp.2008.08071006.
Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialog Clin Neurosci. 2015;17(3):327-335.
Kessler RC, Avenevoli S, Costello J, et al. Prevalence, persistence, and sociodemographic correlates of DSM-IV disorders in the National Comorbidity Survey Replication Adolescent Supplement. Arch Gen Psychiatry. 2012;69(4):372-380. https://doi.org/10.1001/archgenpsychiatry.2011.160.
Chaichana KL, Buffington AL, Brandes M, Edwin D, Lee HB. Treatment of psychiatric comorbidities in a patient with Becker muscular dystrophy. Psychosomatics. 2007;48(2):167-169.
Bardoni A, Sironi M, Felisari G, Comi GP, Bresolin N. Absence of brain Dp140 isoform and cognitive impairment in Becker muscular dystrophy. Lancet. 1999;353:897-898.
Bardoni A, Felisari G, Sironi M, et al. Loss of Dp140 Regulatory sequences is associated with cognitive impairment in dystrophinopathies. Neuromuscul Disord. 2000;10(3):194-199.
Daoud F, Angeard N, Demerre B, et al. Analysis of Dp71 contribution in the severity of mental retardation through comparison of Duchenne and Becker patients differing by mutation consequences on Dp71 expression. Hum Mol Genet. 2009;18(20):3779-3794. https://doi.org/10.1093/hmg/ddp320.
Hodgson S, Hart K, Abbs S, et al. Correlation of clinical and deletion data in Duchenne and Becker muscular dystrophy. J Med Genet. 1989;26(11):682-693.
Hodgson SV, Abbs S, Clark S, et al. Correlation of clinical and deletion data in Duchenne and Becker muscular dystrophy, with special reference to mental ability. Neuromuscul Disord. 1992;2(4):269-276.
Ricotti V, Mandy WP, Scoto M, et al. Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations. Dev Med Child Neurol. 2016;58(1):77-84. https://doi.org/10.1111/dmcn.12922.
Giliberto F, Ferreiro V, Dalamon V, Szijan I. Dystrophin deletions and cognitive impairment in Duchenne/Becker muscular dystrophy. Neurol Res. 2004;26(1):83-87. https://doi.org/10.1179/016164104773026589.
US Food & Drug Administration. Real-world evidence. https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence.
Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence-what is it and what can it tell us? N Engl J Med. 2016;375(23):2293-2297.
North KN, Miller G, Iannaccone ST, et al. Cognitive dysfunction as the major presenting feature of Becker's muscular dystrophy. Neurology. 1996;46(2):461-465.
Desguerre I, Christov C, Mayer M, et al. Clinical heterogeneity of Duchenne muscular dystrophy (DMD): definition of sub-phenotypes and predictive criteria by long-term follow-up. PLoS One. 2009;4(2):e4347. https://doi.org/10.1371/journal.pone.0004347.